Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Limitations of Stem Cell Therapy for Parkinson's Disease

Li Z., Peng S., Ouyang J., Liu R.

Clinical Trial on Neuroinflammation, published in Cells (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Cells (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42121940
PMCID
PMC13162666
DOI
10.3390/cells15090839

Abstract (original English)

Stem cell therapy, as a potential treatment for Parkinson's disease (PD), has been investigated in many clinical trials for its effectiveness. However, the therapeutic outcomes have shown considerable variability. This may be due to certain limitations of stem cell therapies, such as the inability to ameliorate non-motor symptoms or modify underlying disease mechanisms, and the limited applicability in certain patient populations. Combinations with the recently emerging gene therapy and other available technologies are expected to make up for or break down these limitations of stem cell therapy, thereby broadening its scope of application. In this review, we will discuss the limitations of stem cell therapy in terms of pathogenesis, symptoms, and population, as well as possible coping strategies to enhance the effectiveness of stem cell therapy.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Stem CellsAnimalsHumansParkinson DiseaseStem Cell TransplantationGenetic TherapyCell- and Tissue-Based Therapy

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research